U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease PR Newswire

* JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease(1) * Taken once daily with or without levodopa therapy, JUVMO offers patients a differentiated approach to motor symptom control across the Parkinson's disease continuum * Approval is supported by the Phase 3 TEMPO program demonstrating significant improvements in daily functioning, increased "on" time without troublesome dyskinesia and a favorable safety profile NORTH CHICAGO, Ill., Sept. 28, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease, a progressive neurological disorder that affects millions of people worldwide.